References
- Gaulard P SS, Harris NL, Jaffe ES, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH CE, Harris NK, Jaffe ES, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: WHO; 2008. p 350–351.
- Koens L, Senff NJ, Vermeer MH, et al. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: a clinicopathologic and immunophenotypical study of 10 cases. Am J Surg Pathol 2014;38:999–1006.
- Maruani A, Wierzbicka E, Machet MC, et al. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J Am Acad Dermatol 2007;57:S69–71.
- Rausch T, Cairoli A, Benhattar J, et al. EBV+ cutaneous B-cell lymphoproliferation of the leg in an elderly patient with mycosis fungoides and methotrexate treatment. APMIS 2013;121:79–84.
- Tournadre A, D’Incan M, Dubost JJ, et al. Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients treated with methotrexate. Mayo Clin Proc 2001;76:845–848.
- Verma S, Frambach GE, Seilstad KH, et al. Epstein—Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol 2005;32:474–483.
- Giard C, Avenel-Audran M, Croue A, et al. Primary cutaneous Epstein-Barr virus-associated B-cell lymphoma arising at the site of subcutaneous injections of methotrexate. J Clin Oncol 2010;28:e717–718.
- Chai C, White WL, Shea CR, et al. Epstein Barr virus-associated lymphoproliferative-disorders primarily involving the skin. J Cutan Pathol 1999;26:242–247.
- Fam AG, Perez-Ordonez B, Imrie K. Primary cutaneous B cell lymphoma during methotrexate therapy for rheumatoid arthritis. J Rheumatol 2000;27:1546–1549.
- Huwait H, Wang B, Shustik C, et al. Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Am J Dermatopathol 2010;32:65–70.
- Pfistershammer K, Petzelbauer P, Stingl G, et al. Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an ‘angiocentric’ histological morphology. Clin Exp Dermatol 2010;35:59–62.
- Viraben R, Brousse P, Lamant L. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br J Dermatol 1996;135:116–118.
- Clarke LE, Junkins–Hopkins J, Seykora JT, et al. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J Am Acad Dermatol 2007;56:686–690.
- Matsumoto Y, Horiike S, Maekawa S, et al. Rheumatoid arthritis/methotrexate-associated primary cutaneous diffuse large B-cell lymphoma, leg type. Intern Med 2014;53:1177–1181.
- Swerdlow SH WS, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. Lyon: WHO; 2008.
- Baecklund E, Sundstrom C, Ekbom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543–1550.
- Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/ iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 2013;91:20–28.
- Omar H, Hagglund H, Gustafsson-Jernberg A, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis 2009;11:393–399.
- Patsinakidis N, Kreuter A, Moritz RK, et al. Complete remission of refractory, ulcerated, primary cutaneous CD30 + anaplastic large cell lymphoma following brentuximab vedotin therapy. Acta Derm Venereol 2015;95:233–234.
- Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007;34:322–331.
- Rizzi R, Curci P, Delia M, et al. Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 2009;26:1–9.